Guide

No-show plus refill request: the policy that protects both of you

Summary

No single rule dictates the answer, but the safe move is a written policy applied consistently, not a case-by-case guess. For a non-controlled maintenance medication, a short bridge with a firm re-engagement deadline is often reasonable; for a controlled substance, a refill without a current visit is where risk concentrates, and a REMS drug can make the missed monitoring visit a hard stop. Check the PDMP, document the decision, and never simply abandon the patient.

By Gale Editorial · Updated 2026-07-26. Every figure cited to a dated source. How we write.

Is there a single rule? The honest answer

There is no statute that tells you to refill or refuse when a patient keeps missing appointments; the decision sits inside the standard of care and your own written policy. What protects you is consistency — a rule you set in advance and apply the same way to everyone — rather than a tired end-of-day judgment call. The medication class changes everything: a stable non-controlled maintenance drug is a different problem from a controlled substance, and both are different from a drug under a monitoring program.

Start from the clinical question, not the scheduling one. A refill exists to continue treatment you are actively managing, and a pattern of missed visits erodes the monitoring that makes continued prescribing defensible. The move that keeps both of you safe is to name that erosion out loud — in a policy the patient agreed to and in the note — so a bridge refill is a documented clinical decision with conditions, not a reflex that quietly becomes indefinite prescribing without oversight.

Controlled substances change the calculus

For any controlled substance, a refill without a current visit is the highest-risk version of this question, because controlled-substance prescribing must rest on a legitimate medical purpose in the usual course of professional practice — a standard that weakens as monitoring lapses 1Ref 1Drug Enforcement Administration (2026).Diversion Control Division.That controlled-substance prescribing must rest on a legitimate medical purpose in the usual course of professional practice and that Schedule II medications cannot be refilled, raising the stakes of a no-show refill.. Schedule II medications cannot be refilled at all; each fill needs a new prescription, so a no-show patient on a stimulant is asking for a fresh clinical decision every time, not a routine renewal.

Before you write anything, check the PDMP — most states require the query before controlled-substance prescribing, and it is where a pattern of early fills or multiple prescribers shows up 2Ref 2PDMP Training and Technical Assistance Center (2026).Prescription Drug Monitoring Program Training and Technical Assistance Center.That most states mandate a PDMP query before controlled-substance prescribing, the check that surfaces early fills and multiple prescribers before a refill decision.. The schedule ii logistics of stimulants make missed visits especially fraught, and charting the benzodiazepine conversation matters when a sedative is involved. Treat each controlled-substance refill for a no-show patient as a decision you can defend from the record: the PDMP result, the clinical reasoning, and the limit you set.

REMS drugs make the missed visit a hard stop

For a drug under an FDA Risk Evaluation and Mitigation Strategy, the missed visit is not a judgment call — the program can make it a hard stop. Medications like clozapine and esketamine carry REMS requirements that gate dispensing on documented monitoring, so a lapse in the required labs or observation means the pharmacy cannot dispense and you cannot bridge around it 3Ref 3U.S. Food and Drug Administration (2026).Risk Evaluation and Mitigation Strategies (REMS).That FDA REMS programs for drugs such as clozapine and esketamine gate dispensing on documented monitoring, so a missed monitoring visit becomes a hard stop no bridge refill can override.. The REMS is the answer, and it overrides your discretion.

Know which of your prescriptions carry a REMS before this situation arises, and build the monitoring into the visit cadence so a no-show triggers a defined process rather than an improvised one. For a clozapine patient, the monitoring is the treatment's safety backbone; a missed lab is a clinical event to act on, not a scheduling nuisance to waive. Arranging labs without a health system is its own solo problem — solve it before you start the medication, not at the refill request.

Write the policy before you need it

The single most useful artifact here is a written no-show and refill policy the patient signs at intake, so the answer is decided before the pressure of a specific request. A workable policy states how many missed visits change the prescribing relationship, whether and how a short bridge is available, that controlled substances require an in-person or telehealth visit on a set cadence, and what happens if the pattern continues. Consistency applied to everyone is also your defense against a discrimination claim.

Fold controlled-substance terms into a signed agreement covering the visit cadence, the PDMP consent, and the monitoring you require — the same agreement that governs the solo prescriber's schedule and your refill windows. When the policy is explicit, a bridge refill becomes an application of a rule, and a refusal becomes the enforcement of terms the patient already accepted. That is far more defensible than a decision that looks improvised, and it is kinder to the patient, who knows the expectations up front.

The bridge refill: a short, conditional option

When a bridge is clinically appropriate, keep it short, conditional, and documented: a limited supply that carries the patient to a scheduled visit, granted with an explicit re-engagement deadline rather than an open-ended renewal. Pair it with an outreach attempt and, where the barrier is logistical, offer a telehealth visit — for many psychiatric medications a video check-in can re-establish the contact a refill decision needs 4Ref 4American Psychiatric Association (2026).Telepsychiatry Toolkit.That a telehealth visit can re-establish the clinical contact a refill decision needs, offered as the re-engagement mechanism for a patient facing logistical barriers.. The bridge buys time to re-engage; it does not replace the visit.

For a buprenorphine patient the stakes are higher, because an interruption in treatment can precipitate relapse, and SAMHSA frames reliable access and continuity as part of opioid use disorder care 5Ref 5Substance Abuse and Mental Health Services Administration (2026).Buprenorphine.That interruptions in buprenorphine treatment can precipitate relapse and that reliable access and continuity are part of OUD care, making a documented bridge often the safer choice.. There the bridge is often the safer clinical choice, documented alongside the plan to re-engage. Across every class, set the condition in writing — the visit that must happen, by when — so the bridge is a step in active treatment, not a slow drift into unmonitored prescribing.

Document the decision either way — and don't abandon the patient

Whichever way you decide, the note is what protects you, so authenticate it: Medicare and most payers expect each clinical decision to be signed by the responsible prescriber, and the reasoning, the PDMP result, and the conditions belong in the record 6Ref 6Centers for Medicare & Medicaid Services (2023).Complying with Medicare Signature Requirements.That Medicare requires each clinical decision to be authenticated by signature, so the refill decision, its reasoning, and the PDMP result must be documented and signed in the record.. Document the refill you granted and its limits, or the refill you declined and why, along with the outreach you made and the plan you offered. A clean record turns a contested decision into a defensible one.

Just as important, do not simply cut off a patient who keeps missing visits. Abruptly stopping prescriptions and dropping the patient can raise a patient-abandonment concern; the operational safeguard is reasonable written notice, a bridge where clinically indicated, and referral to continuing care. Ending a treatment relationship is sometimes right, but it is done through a documented, orderly transition — not by silence at the pharmacy counter.

Common questions

Not inherently, but it is risky. There is no blanket law against refilling between visits, yet controlled-substance prescribing must rest on a legitimate medical purpose in the usual course of practice, and Schedule II drugs cannot be refilled at all. For non-controlled medications a short documented bridge is often reasonable. The safest posture is a written policy, a PDMP check for controlled substances, and a clear note.

Long enough to reach the next scheduled visit and no longer. A bridge is meant to carry the patient to an appointment you have actually booked, tied to an explicit re-engagement deadline — not an open renewal. Keep it short, document the condition attached to it, and confirm the visit happens. For controlled substances, the shorter and more conditional the bridge, the more defensible your record.

Then the REMS decides, not you. Drugs under an FDA Risk Evaluation and Mitigation Strategy, such as clozapine and esketamine, gate dispensing on documented monitoring, so a missed required lab or observation means the pharmacy cannot dispense and there is no bridge around it. Build the monitoring into the visit cadence, treat a missed lab as a clinical event, and arrange the testing before starting the medication.

Yes, but end the relationship deliberately, not by silence. Abruptly cutting off prescriptions and dropping a patient can raise a patient-abandonment concern. The safeguard is a documented, orderly transition: reasonable written notice, a bridge where clinically indicated so the patient is not left in withdrawal or destabilized, and referral to continuing care. Terminating treatment is sometimes appropriate, but it is done through process, not at the pharmacy counter.

Yes — a signed no-show and refill policy at intake is the most useful thing you can have. It should state how missed visits change the prescribing relationship, whether a bridge is available and on what terms, and that controlled substances require a visit on a set cadence with PDMP consent. Applied consistently to everyone, it turns each refill request into an application of a rule rather than an improvised call.

Run your practice on Gale

The software is free. Gale earns one flat 3.5% all-in per paid transaction — only on transactions that actually pay. No subscription, no setup fee, no network cut.

Start or manage a practice →

References

1.Drug Enforcement Administration (2026). Diversion Control Division. U.S. Drug Enforcement Administration. link ✓That controlled-substance prescribing must rest on a legitimate medical purpose in the usual course of professional practice and that Schedule II medications cannot be refilled, raising the stakes of a no-show refill.
2.PDMP Training and Technical Assistance Center (2026). Prescription Drug Monitoring Program Training and Technical Assistance Center. PDMP TTAC (Brandeis University, BJA-funded). link ✓That most states mandate a PDMP query before controlled-substance prescribing, the check that surfaces early fills and multiple prescribers before a refill decision.
3.U.S. Food and Drug Administration (2026). Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration. link ✓That FDA REMS programs for drugs such as clozapine and esketamine gate dispensing on documented monitoring, so a missed monitoring visit becomes a hard stop no bridge refill can override.
4.American Psychiatric Association (2026). Telepsychiatry Toolkit. American Psychiatric Association. link ✓That a telehealth visit can re-establish the clinical contact a refill decision needs, offered as the re-engagement mechanism for a patient facing logistical barriers.
5.Substance Abuse and Mental Health Services Administration (2026). Buprenorphine. SAMHSA. link ✓That interruptions in buprenorphine treatment can precipitate relapse and that reliable access and continuity are part of OUD care, making a documented bridge often the safer choice.
6.Centers for Medicare & Medicaid Services (2023). Complying with Medicare Signature Requirements. CMS Medicare Learning Network (MLN905364). link ✓That Medicare requires each clinical decision to be authenticated by signature, so the refill decision, its reasoning, and the PDMP result must be documented and signed in the record.

https://www.gale.care/for-providers/bhp-no-show-refill-requests · 6 sources. Competitor details are cited to dated public sources and maintained as they change; figures are estimates, not commitments. Synthetic demonstration.

← Back to for providers